Kalypsys, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kalypsys, Inc.
Generic Drugs: ‘Competitive’ Exclusivity Benefited Few Sponsors But Is Increasingly Popular
The six months of additional exclusivity from US FDA’s CGT program appears to have kept some generic sponsors from the market, and didn’t even prompt others to enter quickly, but use of the competitive generic exclusivity program continues to grow.
Caplin Partners With Xellia For Five Injectables
With a pipeline of over 35 ANDAs, India's Caplin Steriles plans to launch five generic injectables through a strategic partnership with Xellia Pharma in the US market. Out of the five ANDAs, one has been approved and is ready for launch.
Deals Of The Week: Merck/Calibr, GSK/Epistem, Biogen Idec/MAKScientific
Shire addresses its Replagal disappointment with the acquisition of FerroKin and its hematology pipeline.
Merck Ups The Calibr Of Academic-Industry Cooperation
Merck announced March 15 that it plans to invest $90 million over the next seven years in a nonprofit biomedical research center in San Diego dubbed the California Institute for Biomedical Research, or Calibr.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice